Michel Bouvier, MD, PhD, serves as the Chief Executive Officer of the Institute for Research in Immunology and Cancer (IRIC). Dr. Bouvier is a professor in the Department of Biochemistry and Molecular Medicine at the University of Montreal. He has been the Chair of the Scientific Advisory Board at Domain Therapeutics S.A since September 2014 andhas served as a member of the scientific advisory boards at Amicus Therapeutics, Inc., Sodexo S.A., 7TM Pharma A/s, and Hybrigenics Société Anonyme. He was also as a member of Advisory Committee at T2C2/Bio 2000, L.P. A world expert on 7TM receptor pharmacology and biochemistry with major contributions concerning post-translational modifications and their role in regulating receptor function, he is the major authority in the field of 7TM receptor dimerization, a highly topical area that he pioneered and where he developed novel analytical tools including Bioluminescence Resonance Energy Transfer. Recently, he established a new pharmacological principle called pharmacological chaperones, small organic compounds that can rescue mal-folded proteins, especially 7TM receptors. Dr. Bouvier was awarded the Hans-Selye/Bristo Myers Squibb Chair in Cell and Molecular Biology and the Merck-Frosst Award from the Canadian Society of Biochemistry and Molecular & Cell Biology. He holds the Canada Research Chair in Signal Transduction and Molecular Pharmacology and is a fellow of the Canadian Academy of Health Sciences and of the Roy Society of Canada. He conducted postdoctoral training at Duke University.